Actively Recruiting
68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases
Led by University Hospital, Brest · Updated on 2026-03-04
390
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the use of the imaging agent 68Ga Ga-FAPI in PET/CT scans to explore its potential in diagnosing and monitoring various chronic inflammatory and fibrotic diseases. This pilot study involves 13 different clinical conditions such as rheumatoid arthritis, liver fibrosis, systemic lupus, and others. The goal is to determine if this new imaging method can improve disease evaluation and support further clinical development in these areas. The study adds a 68Ga Ga-FAPI PET/CT scan to usual routine care. Depending on the condition and treatment plan, patients may have this scan once at the start or multiple times over 3 to 6 months if their therapy is intensified. This imaging agent targets the fibroblast activation protein (FAP), which is involved in tissue remodeling and fibrosis, helping to highlight disease activity in affected tissues. Participants will undergo the PET/CT scans along with routine clinical evaluations and may be followed up at baseline, 3 months, and 6 months. Researchers will measure PET uptake intensity and correlate imaging results with pathology findings, biomarkers, functional parameters, and imaging characteristics over time. The study aims to assess the usefulness of 68Ga Ga-FAPI PET/CT in improving diagnosis and monitoring of these chronic diseases while participants continue their usual care.
CONDITIONS
Brief Title
68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 18 or over
- Diagnosed with one of the specific chronic inflammatory or fibrotic diseases included in the study
- Meets consensus classification criteria for the disease
- Meets the corresponding clinical situation criteria
- Negative urine pregnancy test for women of childbearing age
- Affiliated with or benefiting from social security
- Provides informed consent personally signed or with a trusted representative
You will not qualify if you...
- Unable to provide consent
- Incapacitated adults
- Pregnant or breastfeeding women
- Refusal to participate in research
- Known active cancer
- Women of childbearing potential not using appropriate contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 months
Participants undergo 68Ga-FAPI46 PET/CT imaging to evaluate chronic inflammatory and fibrotic diseases. This includes a baseline scan, and for some participants, additional scans at 3 and 6 months depending on their therapeutic management.
1 baseline visit and up to 2 follow-up visits at 3 and 6 months
Trial Site Locations
Total: 1 location
1
Chu Brest
Brest, France, 29200
Actively Recruiting
Research Team
P
Pierre-Yves LE ROUX, PHD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here